Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=program_officials", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=program_officials" }, "data": [ { "type": "Grant", "id": "14723", "attributes": { "award_id": "4R00CA277136-02", "title": "Modifiable Determinants of Disparities in Multiple Myeloma Treatment Patterns", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31412, "first_name": "AMY", "last_name": "DAVIDOFF", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-02-01", "end_date": "2027-01-31", "award_amount": 248999, "principal_investigator": { "id": 27010, "first_name": "Hamlet", "last_name": "Gasoyan", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1013, "ror": "", "name": "CLEVELAND CLINIC LERNER COM-CWRU", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "In this K99/R00 Pathway to Independence Award for Outstanding Early-Stage Postdoctoral Researchers application, Dr. Hamlet Gasoyan outlines a detailed proposal to enhance his research training in cancer disparities research in tandem with examining the modifiable determinants of treatment-related disparities in patients with multiple myeloma (MM). A primary goal of Dr. Gasoyan is to become an independent and productive investigator in the field of cancer health disparities, with a research focus on obesity-related cancers. His short-term training objectives for the K99 Mentored Training are to (1) advance his knowledge and skills in cancer disparities research; (2) advance his skills in analyzing EHR-generated clinical and large administrative data for health services research; and (3) gain experience and skills required to successfully lead a research lab and engage with medical practitioners, community members, and health care policymakers. MM is the second most common hematologic malignancy in the US with an estimated 34,920 incident cases and 12,410 lethal outcomes to occur in 2021. Black individuals have a dramatically higher incidence of MM, as well as a higher rate of MM mortality, compared with White individuals, likely due to several, complex risk factors, such as genetics and differences in exposure to established MM risk factors, such as obesity. Treatment of MM is costly, with one of the highest lifetime net costs among all cancer sites. While novel treatment agents and regimens are available, newly diagnosed Black patients are less likely to undergo stem cell transplantation, use prescription oral medication lenalidomide, or be treated with triplet (3-drug) regimens, such as bortezomib, lenalidomide, and dexamethasone, than their White peers. Furthermore, Black patients receive these novel therapies later compared to their White peers. Given the high cost of treatment, health insurance coverage likely has an important role in racial disparities of accessing novel therapies for MM. Nevertheless, the role of uninsurance or underinsurance in MM care patterns was not well studied. Furthermore, while the COVID-19 pandemic has made presenting for in-person medical care even more challenging, particularly for individuals from underserved communities, no study to date investigated the impact of the COVID-19 pandemic on disparities in MM care patterns. The aims of the proposed research plan are to (1) examine whether determinants patients' insurance coverage and social of health can explain the racial disparities in MM treatment patterns, (2) assess the effects of the COVID-19 pandemic on MM care patterns, and (3) assess whether payer type and cost-sharing arrangements are associated with disparities in the utilization of induction therapy for MM with triplet regimens as well as maintenance therapy with prescription oral medications, such as lenalidomide.", "keywords": [ "Adult", "American", "Area", "Award", "Biology", "Black Populations", "Bortezomib", "COVID-19 pandemic", "COVID-19 pandemic effects", "Cancer Center", "Caring", "Cessation of life", "Clinical", "Communities", "Complex", "Cost Sharing", "Data", "Databases", "Death Rate", "Deductibles", "Dexamethasone", "Diagnosis", "Disparity", "Drug Prescriptions", "Electronic Health Record", "Exposure to", "Genetic", "Goals", "Health", "Health Insurance", "Health Policy", "Health Services Research", "Healthcare", "Hematologic Neoplasms", "Incidence", "Individual", "Inpatients", "Insurance", "Insurance Coverage", "Knowledge", "Lead", "Maintenance Therapy", "Medicaid", "Medical", "Medicare", "Mentors", "Multiple Myeloma", "Neoadjuvant Therapy", "Newly Diagnosed", "Obesity", "Obesity associated cancer", "Oral", "Outcome", "Outpatients", "Pathway interactions", "Patients", "Patterns of Care", "Persons", "Pharmaceutical Preparations", "Phase", "Policy Maker", "Postdoctoral Fellow", "Productivity", "Race", "Regimen", "Research", "Research Personnel", "Research Training", "Retrospective cohort", "Risk Factors", "Role", "Stem cell transplant", "Time", "Training", "Treatment Cost", "Treatment Protocols", "Triplet Multiple Birth", "Underserved Population", "Uninsured Medical Expense", "Urbanicity", "access disparities", "black patient", "cancer health disparity", "cancer site", "care costs", "cost", "deprivation", "experience", "follower of religion Jewish", "health data", "health plan", "indexing", "lenalidomide", "member", "mortality", "novel", "novel therapeutics", "outcome disparities", "pandemic disease", "peer", "pre-pandemic", "racial disparity", "racial population", "residence", "skills", "social", "social health determinants", "treatment pattern", "underserved community" ], "approved": true } }, { "type": "Grant", "id": "14739", "attributes": { "award_id": "1R01HL172048-01", "title": "Molecular pathogenesis of COVID-19-associated coagulopathy and new therapeutic approaches", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31426, "first_name": "CRYSTAL DARLEANE-ROBIN", "last_name": "Hill-Pryor, Ph.D., MPH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-01-01", "end_date": "2028-12-31", "award_amount": 650342, "principal_investigator": { "id": 31427, "first_name": "Roberto", "last_name": "Aiolfi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 745, "ror": "", "name": "SCRIPPS RESEARCH INSTITUTE, THE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Many studies have highlighted a large incidence of hemostatic derangements in the form of hypercoagulable and hypofibrinolytic states following SARS-CoV-2 infection. These hemostatic disturbances are fueled by and a consequence of the concomitant activation of the endothelium following a severe inflammatory response, with likely contribution from many other pathways and components, such as the complement pathway and neutrophil activation. In COVID-19 patients, the resulting hyperinflammation, vascular dysfunction, and systemic hypercoagulability, collectively referred to as COVID-19-associated coagulopathy (CAC), manifests as the increased tendency of micro-thrombosis of different organs leading to organ dysfunction, venous thromboembolism, pulmonary embolism, and deep vein thrombosis. Reducing the deleterious impact of CAC during severe SARS-CoV-2 infections continues to represent a major therapeutic challenge. Despite the enormous effort exerted during the pandemic to understand the pathological mechanisms responsible for the severity of SARS-CoV-2 infections, a major knowledge gap about the drivers and mechanisms underlying CAC still exists. Furthermore, as the link between CAC and long COVID becomes more apparent, understanding CAC is more urgent than ever. Proposed studies are designed to gain knowledge on the drivers and mechanisms underlying CAC and will test the feasibility of several potential pharmacological approaches to blunt it. Levering our novel and carefully optimized mouse model of COVID-19 and CAC, relying on a human pathological SARS- CoV-2 strain and recapitulating major pathological alterations and development of CAC observed in human patients presents a unique opportunity for hypotheses-driven research in a controlled and systematic manner to gain important new insights on CAC. Mimicking worldwide observations that males are more susceptible to severe disease after SARS-CoV-2 infection compared to females, a sex-dependent bias in disease severity was also observed in our model that was accompanied by striking temporal, quantitative, and qualitative differences in the development of CAC. Aim 1 will characterize the major molecular determinants of the sex-biased disease severity and development of CAC in our mouse model of COVID-19 and CAC. Key questions that will be addressed are the extent to which the sex bias originates from hormonal differences, whether estrogens are protective and/or androgens are deleterious, and whether hormonal supplementation therapy can alter the development of CAC. These studies will help identify novel pathways and targets for CAC. Aim 2 will expand on our preliminary data to characterize von Willebrand Factor (VWF)’s function(s) and protein/protein interaction(s) that are responsible for modulating survival during SARS-CoV-2 infection and development of CAC. The results of these studies will increase our knowledge of the mechanisms involved in regulating the finely tuned interaction between the immune, endothelial, and coagulation systems upon SARS-CoV-2 infection, possibly leading to the identification of new therapeutical targets for the treatment of CAC.", "keywords": [ "2019-nCoV", "ACE2", "Address", "Androgens", "Automobile Driving", "Basic Science", "Biology", "Blood Coagulation Disorders", "Blood Platelets", "COVID-19", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 pathogenesis", "COVID-19 patient", "COVID-19 prevention", "COVID-19 severity", "COVID-19 susceptibility", "COVID-19 treatment", "Cells", "China", "Clinical", "Coagulation Process", "Complex", "Data", "Deep Vein Thrombosis", "Development", "Disease", "Disease Progression", "Endothelium", "Estrogens", "Female", "Fibrin", "Functional disorder", "Goals", "Hemostatic Agents", "Hemostatic function", "Hormonal", "Hormones", "Host Defense Mechanism", "Human", "Immune", "Immune Targeting", "Immune response", "Incidence", "Infection", "Inflammatory Response", "Intervention Studies", "K-18 conjugate", "Knowledge", "Link", "Long COVID", "Mediating", "Modeling", "Molecular", "Mus", "Names", "Neutrophil Activation", "Organ", "Outcome", "Pathologic", "Pathway interactions", "Patients", "Play", "Predisposition", "Proteins", "Pulmonary Embolism", "Recovery", "Reporting", "Research", "Research Personnel", "Respiratory Disease", "Risk", "Role", "SARS-CoV-2 infection", "Severities", "Severity of illness", "Sex Bias", "Sex Differences", "Sexual Development", "Specificity", "Supplementation", "Syndrome", "System", "Therapeutic", "Therapeutic Effect", "Therapeutic Intervention", "Thrombophilia", "Thrombosis", "Thrombus", "Time", "Translational Research", "Vascular Diseases", "Virus", "Virus Diseases", "combat", "complement pathway", "design", "efficacy testing", "experience", "extracellular", "feasibility testing", "immune activation", "immunothrombosis", "in vivo", "insight", "male", "molecular targeted therapies", "monocyte", "mortality", "mouse model", "neutrophil", "new therapeutic target", "novel", "novel strategies", "novel therapeutic intervention", "novel therapeutics", "pandemic disease", "pathogen", "pathogenic virus", "pharmacologic", "platelet function", "post SARS-CoV-2 infection", "recruit", "response", "severe COVID-19", "sex", "success", "targeted treatment", "thromboinflammation", "venous thromboembolism", "von Willebrand Factor" ], "approved": true } }, { "type": "Grant", "id": "15554", "attributes": { "award_id": "5R01HL172048-02", "title": "Molecular pathogenesis of COVID-19-associated coagulopathy and new therapeutic approaches", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31426, "first_name": "CRYSTAL DARLEANE-ROBIN", "last_name": "Hill-Pryor, Ph.D., MPH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-01-01", "end_date": "2028-12-31", "award_amount": 659826, "principal_investigator": { "id": 31427, "first_name": "Roberto", "last_name": "Aiolfi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 745, "ror": "", "name": "SCRIPPS RESEARCH INSTITUTE, THE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Many studies have highlighted a large incidence of hemostatic derangements in the form of hypercoagulable and hypofibrinolytic states following SARS-CoV-2 infection. These hemostatic disturbances are fueled by and a consequence of the concomitant activation of the endothelium following a severe inflammatory response, with likely contribution from many other pathways and components, such as the complement pathway and neutrophil activation. In COVID-19 patients, the resulting hyperinflammation, vascular dysfunction, and systemic hypercoagulability, collectively referred to as COVID-19-associated coagulopathy (CAC), manifests as the increased tendency of micro-thrombosis of different organs leading to organ dysfunction, venous thromboembolism, pulmonary embolism, and deep vein thrombosis. Reducing the deleterious impact of CAC during severe SARS-CoV-2 infections continues to represent a major therapeutic challenge. Despite the enormous effort exerted during the pandemic to understand the pathological mechanisms responsible for the severity of SARS-CoV-2 infections, a major knowledge gap about the drivers and mechanisms underlying CAC still exists. Furthermore, as the link between CAC and long COVID becomes more apparent, understanding CAC is more urgent than ever. Proposed studies are designed to gain knowledge on the drivers and mechanisms underlying CAC and will test the feasibility of several potential pharmacological approaches to blunt it. Levering our novel and carefully optimized mouse model of COVID-19 and CAC, relying on a human pathological SARS- CoV-2 strain and recapitulating major pathological alterations and development of CAC observed in human patients presents a unique opportunity for hypotheses-driven research in a controlled and systematic manner to gain important new insights on CAC. Mimicking worldwide observations that males are more susceptible to severe disease after SARS-CoV-2 infection compared to females, a sex-dependent bias in disease severity was also observed in our model that was accompanied by striking temporal, quantitative, and qualitative differences in the development of CAC. Aim 1 will characterize the major molecular determinants of the sex-biased disease severity and development of CAC in our mouse model of COVID-19 and CAC. Key questions that will be addressed are the extent to which the sex bias originates from hormonal differences, whether estrogens are protective and/or androgens are deleterious, and whether hormonal supplementation therapy can alter the development of CAC. These studies will help identify novel pathways and targets for CAC. Aim 2 will expand on our preliminary data to characterize von Willebrand Factor (VWF)’s function(s) and protein/protein interaction(s) that are responsible for modulating survival during SARS-CoV-2 infection and development of CAC. The results of these studies will increase our knowledge of the mechanisms involved in regulating the finely tuned interaction between the immune, endothelial, and coagulation systems upon SARS-CoV-2 infection, possibly leading to the identification of new therapeutical targets for the treatment of CAC.", "keywords": [ "2019-nCoV", "ACE2", "Address", "Androgens", "Automobile Driving", "Basic Science", "Biology", "Blood Coagulation Disorders", "Blood Platelets", "COVID-19", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 pathogenesis", "COVID-19 patient", "COVID-19 prevention", "COVID-19 severity", "COVID-19 susceptibility", "COVID-19 treatment", "Cells", "China", "Clinical", "Coagulation Process", "Complex", "Data", "Deep Vein Thrombosis", "Development", "Disease", "Disease Progression", "Endothelium", "Estrogens", "Female", "Fibrin", "Functional disorder", "Goals", "Hemostatic Agents", "Hemostatic function", "Hormonal", "Hormones", "Host Defense Mechanism", "Human", "Immune", "Immune Targeting", "Immune response", "Incidence", "Infection", "Inflammatory Response", "Intervention Studies", "K-18 conjugate", "Knowledge", "Link", "Long COVID", "Mediating", "Modeling", "Molecular", "Mus", "Names", "Neutrophil Activation", "Organ", "Outcome", "Pathologic", "Pathway interactions", "Patients", "Play", "Predisposition", "Proteins", "Pulmonary Embolism", "Recovery", "Reporting", "Research", "Research Personnel", "Respiratory Disease", "Risk", "Role", "SARS-CoV-2 infection", "Severities", "Severity of illness", "Sex Bias", "Sex Differences", "Sexual Development", "Specificity", "Supplementation", "Syndrome", "System", "Therapeutic", "Therapeutic Effect", "Therapeutic Intervention", "Thrombophilia", "Thrombosis", "Thrombus", "Time", "Translational Research", "Vascular Diseases", "Virus", "Virus Diseases", "combat", "complement pathway", "design", "efficacy testing", "extracellular", "feasibility testing", "immune activation", "immunothrombosis", "in vivo", "insight", "male", "mens experience", "molecular targeted therapies", "monocyte", "mortality", "mouse model", "neutrophil", "new therapeutic target", "novel", "novel strategies", "novel therapeutic intervention", "novel therapeutics", "pandemic disease", "pathogen", "pathogenic virus", "pharmacologic", "platelet function", "post SARS-CoV-2 infection", "recruit", "response", "severe COVID-19", "sex", "success", "targeted treatment", "thromboinflammation", "venous thromboembolism", "von Willebrand Factor" ], "approved": true } }, { "type": "Grant", "id": "14755", "attributes": { "award_id": "1F32HD114427-01", "title": "Transcriptional variation in human milk", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 31451, "first_name": "KIMBERLEA", "last_name": "Gibbs", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-01-01", "end_date": "2026-12-31", "award_amount": 69080, "principal_investigator": { "id": 31452, "first_name": "Sarah Kate", "last_name": "Nyquist", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 917, "ror": "", "name": "J. DAVID GLADSTONE INSTITUTES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Centers for Disease Control recommends breastfeeding for the first six months of an infant’s life due to significant long term health benefits for the infant and breastfeeding parent. Beyond meeting the nutritional needs of the infant, human milk is a dynamic fluid with composition that changes to meet the needs of the infant as it develops and bioactive components which provide protective immunity to the infant. However, much is still unknown about the cells in the mammary gland which produce these prized components of human milk. Currently, there are no FDA approved interventions known to boost milk production, so the 60-70% of parents who struggle to lactate are left with little support to improve lactation outcomes and set infants up for the long- term health benefits of breastfeeding. Recent studies using single cell RNA-sequencing (scRNA-seq) of the mammary gland cells exfoliated into human milk have begun to characterize the cells that produce this dynamic substance with the ultimate goal of improving understanding of the factors impacting milk production at a cellular level. Still, the transcriptional pathways involved in milk production as well as the way these pathways change as a result of maternal and infant factors remains poorly understood. This proposal will utilize existing data generated from human milk to improve the understanding of transcriptional basis of milk production by (1) using integrative analysis of existing scRNA-seq data to identify shared transcriptional pathways of lactation, (2) developing statistical models to expose genes and pathways that change in milk in concordance with maternal and infant characteristics, COVID-19 infection and vaccination, antibody concentrations, and human milk oligosaccharide concentration, and (3) apply these and other models to understand the changes in the mammary gland and milk composition as a result of COVID-19 infection and vaccination. This improved characterization of milk production will lead to future studies on interventions to improve lactation outcomes and immune protection from human milk. Research will take place at the Gladstone Institute of Data Science and Biotechnology, a highly collaborative research institution with a commitment to postdoctoral training. The trainee with receive training in statistical analysis and method development, lactation biology, immunology, and responsible conduct of research from an interdisciplinary and multi-institutional team of mentors and collaborators. The training plan will prepare the trainee for an independent career as a computational biologist studying lactation and maternal and infant health.", "keywords": [ "Age Months", "Anabolism", "Antibodies", "Area", "Biological", "Biological Process", "Biological Response Modifiers", "Biology", "Biotechnology", "Blood", "Blood specimen", "Breast Feeding", "COVID-19", "COVID-19 booster", "COVID-19 vaccination", "Cell Physiology", "Cells", "Centers for Disease Control and Prevention (U.S.)", "Characteristics", "Clinical", "Data", "Data Science", "Data Set", "Disease", "Epithelial Cells", "Exposure to", "FDA approved", "Family", "Future", "Genes", "Genetic Transcription", "Goals", "Health", "Health Benefit", "Human Milk", "Immune", "Immunity", "Immunology", "Individual", "Infant", "Infant Development", "Infant Health", "Infection", "Institution", "Interdisciplinary Study", "Intervention", "Knowledge", "Lactation", "Left", "Life", "Lipids", "Liquid substance", "Maintenance", "Mammary gland", "Maternal Health", "Measurement", "Mentors", "Metabolic", "Methods", "Milk", "Modeling", "Nature", "Nutrient", "Nutritional", "Outcome", "Parents", "Pathway interactions", "Process", "Production", "Publishing", "Recommendation", "Research", "Role", "SARS-CoV-2 infection", "Sample Size", "Sampling", "Secondary Immunization", "Statistical Data Interpretation", "Statistical Methods", "Statistical Models", "Stimulus", "Techniques", "Time", "Training", "Vaccination", "Variant", "Viral Vaccines", "Virus Diseases", "Work", "antibody transfer", "career", "human data", "human milk oligosaccharides", "improved", "infant nutrition", "interest", "mammary", "meetings", "method development", "milk production", "milk supply", "mortality", "novel", "post-doctoral training", "programs", "response", "responsible research conduct", "single-cell RNA sequencing", "tool", "transcriptomics" ], "approved": true } }, { "type": "Grant", "id": "14756", "attributes": { "award_id": "1R01CA276107-01A1", "title": "Control of cancer cachexia via stimulation of resolution of inflammation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31453, "first_name": "Marge", "last_name": "Good", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-01-01", "end_date": "2028-12-31", "award_amount": 709923, "principal_investigator": { "id": 31454, "first_name": "Steven David", "last_name": "Freedman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 31455, "first_name": "Dipak", "last_name": "Panigrahy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 31456, "first_name": "Charles Nicholas", "last_name": "Serhan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 771, "ror": "https://ror.org/04drvxt59", "name": "Beth Israel Deaconess Medical Center", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "While cancer cachexia is a devastating syndrome characterized by progressive muscle wasting, inflammation, and metabolic disruption, the underlying mechanisms remain poorly characterized. There are currently no treatments for cachexia. Cancer cachexia is driven by systemic inflammation, pro-inflammatory cytokines, and apoptosis (“cellular debris”). A paradigm shift is emerging in understanding the resolution of inflammation as an active biochemical process with our discovery of novel specialized pro-resolving mediators (SPMs), such as resolvins and endogenous resolution programs. SPMs stimulate macrophage-mediated clearance of debris, promote tissue/muscle regeneration, and counter-regulate pro-inflammatory cytokines at nanogram doses without immunosuppression. Despite approaches to block systemic inflammation, there are no current “pro- resolving” therapies in cancer or cancer cachexia. Moreover, the impact of cancer cachexia on eicosanoids and the novel pro-resolving lipid mediators, both key endogenous regulators of initiation and resolution of inflammation, are unknown. This proposal builds on our recent finding that stimulating resolution of inflamma- tion prevents tumor growth by counter-regulating pro-inflammatory cytokines/eicosanoids and clearing debris. Therefore, the overarching theme is to elucidate the underlying processes of failed resolution of inflamma- tion that drive cancer cachexia. We will rely on a set of established experimental systems, including genetic and pharmacological manipulation of SPMs and their receptors in animal models and macrophages. We shall test this in a multi-pronged approach. In Specific Aim 1, the mechanisms of dysregulated resolution of in- flammation in cachexia will be investigated. We will profile lipid autacoid mediators, including eicosanoids and SPMs, to test our innovative hypothesis that failed resolution of inflammation is necessary and sufficient to cause cachexia, which induces a rapid eicosanoid storm with dysregulated SPMs that leads to an un- controlled cytokine storm. We will evaluate pro-resolving lipid mediators as interventional targets in ca- chexia. In Specific Aim 2, we will optimize the delivery of SPM mimetics and humanized nano-pro- resolving medicines (NPRMs) carrying SPM cargo to cachectic tissues and determine whether SPMs can prevent chemotherapy-induced cachexia. These studies will complement Specific Aim 3, which seeks to pre- vent cancer cachexia via stimulation of resolution by precision nutrition. Parabiosis studies will determine whether cancer-induced cachexia is caused by an effect on the primary tumor or the metastatic site as most patients with cachexia die from metastases. These studies can offer a new animal system to evaluate cachexia at an early stage. We will connect our preclinical findings to clinical disease phenotypes using a computational framework to understand failed inflammation resolution in cachexia. Since SPMs have proven safe and effec- tive in human inflammatory disorders, these studies shall provide the basis for rapid translation of resolution- directed treatments in humans as a new direction to potentially prevent and/or reverse cancer cachexia.", "keywords": [ "Acceleration", "Adipocytes", "Advanced Malignant Neoplasm", "Animal Model", "Animals", "Anti-Inflammatory Agents", "Apoptosis", "Apoptotic", "Autacoids", "Biochemical Process", "Body Weight decreased", "CD59 Antigen", "Cachexia", "Cancer Cachexia", "Cancer Control", "Cancer Etiology", "Cancer Patient", "Catabolism", "Cell Death", "Cells", "Cessation of life", "Clinical", "Clinical Trials", "Complement", "Deterioration", "Disease", "Dose", "Eicosanoids", "Excision", "Exhibits", "Fatty acid glycerol esters", "Genetic", "Heart", "Homeostasis", "Human", "Human body", "Immunosuppression", "Induction of Apoptosis", "Inflammation", "Inflammation Mediators", "Inflammatory", "Intervention", "Lipids", "Liver", "Lung", "Lymphocyte", "Macrophage", "Malignant Neoplasms", "Mediating", "Mediator", "Medical", "Medicine", "Metabolic", "Metabolic dysfunction", "Micrometastasis", "Modeling", "Molecular", "Multiple Organ Failure", "Mus", "Muscle", "Muscular Atrophy", "Necrosis", "Neoplasm Metastasis", "Nutritional", "Parabiosis", "Patients", "Phagocytosis", "Phase", "Plasma", "Prevention", "Primary Neoplasm", "Process", "Recurrent tumor", "Regulation", "Research Personnel", "Resolution", "Role", "Site", "Skeletal Muscle", "Spleen", "Syndrome", "System", "Testing", "Tissues", "Toxic effect", "Translations", "Wasting Syndrome", "adipokines", "cancer therapy", "chemotherapy", "clinical translation", "computer framework", "control trial", "cytokine", "cytokine release syndrome", "cytotoxic", "disease phenotype", "innovation", "lipid mediator", "mimetics", "muscle regeneration", "nano", "novel", "novel strategies", "pharmacologic", "pre-clinical", "precision nutrition", "prevent", "programs", "protein degradation", "receptor", "repaired", "restoration", "skeletal muscle wasting", "small molecule", "systemic inflammatory response", "tissue regeneration", "tumor", "tumor growth", "tumor progression" ], "approved": true } }, { "type": "Grant", "id": "14758", "attributes": { "award_id": "1R13TR004885-01", "title": "Delivery of Nucleic Acid Therapeutics", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 31458, "first_name": "LINDA DONNA", "last_name": "Ho", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-01-16", "end_date": "2025-01-15", "award_amount": 16500, "principal_investigator": { "id": 27075, "first_name": "TERRY L.", "last_name": "SHEPPARD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1633, "ror": "", "name": "KEYSTONE SYMPOSIA", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Support is requested for a Keystone Symposia conference entitled Delivery of Nucleic Acid Therapeutics, organized by Drs. Daniel Siegwart and Kathryn Whitehead. The conference will be held in Banff, Alberta, Canada from January 22-25, 2024. This conference will bring together world-renowned experts to explore the complex science, engineering, and application of nucleic acid delivery systems. The recent overwhelming success of mRNA-based SARS-CoV-2 vaccines has refocused attention on the potential of nucleic acids as medicines. Despite steady progress over decades, the broad application of nucleic acid therapies relies on the development of enabling delivery systems. This conference will highlight cutting-edge strategies to transport nucleic acids into target cells and organs without toxicity, address the challenges of delivering nucleic acids systemically and intracellularly and emphasize exciting clinical applications of nucleic acid delivery technologies. This conference will provide a rare opportunity to convene experts from a broad array of disciplines, including engineering, materials science, biology, chemistry, and medicine with a focus on nucleic acid delivery, which will facilitate stimulating conversations that will guide future development of the field. One aspect that makes this conference completely unique is that it will be held jointly with another Keystone Symposia meeting entitled “Precision Genome Engineering.” Through the joint sessions, attendees will hear from leaders in the gene editing field, Drs. Jennifer Doudna and Feng Zhang, and these and other sessions will facilitate more engagement between these aligned communities. Attendees will leave the conference with an expanded network of colleagues, armed with a new appreciation for delivery challenges, solutions, and applications. Ultimately, these experiences will catalyze the development and execution of new ideas that will bring many more nucleic acid therapies to fruition.", "keywords": [ "Address", "Alberta province", "Area", "Attention", "Automobile Driving", "Basic Science", "Biology", "COVID-19 vaccine", "Canada", "Cells", "Chemistry", "Collaborations", "Communities", "Complex", "DNA", "Development", "Discipline", "Disease", "Drug Delivery Systems", "Educational workshop", "Engineering", "Future", "Gene Delivery", "Genes", "Genetic Medicine", "Genome engineering", "Hearing", "Industrialization", "International", "Joints", "Knowledge", "Learning", "Liver", "Medical", "Medicine", "Mentors", "Messenger RNA", "Methodology", "Nucleic Acids", "Organ", "Outcome", "Pharmaceutical Preparations", "RNA", "Reagent", "Research", "Research Personnel", "Research Priority", "Science", "Scientist", "Specificity", "System", "Technology", "Therapeutic", "Tissues", "Toxic effect", "Translational Research", "Vaccines", "clinical application", "clinical practice", "design", "experience", "improved", "materials science", "meetings", "method development", "multidisciplinary", "novel", "nucleic acid delivery", "nucleic acid-based therapeutics", "posters", "prospective", "small molecule", "success", "symposium", "targeted delivery", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "14760", "attributes": { "award_id": "1K24HL168225-01A1", "title": "Mentoring and Patient-Oriented Research in Clinical Informatics and Data Science", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31460, "first_name": "BEENA G", "last_name": "Sood", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-12-01", "end_date": "2028-11-30", "award_amount": 125901, "principal_investigator": { "id": 8404, "first_name": "Tellen", "last_name": "Bennett", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "This K24 mid-career investigator award in patient-oriented research is to support the mentoring, research, and career development activities of Dr. Tell Bennett. Dr. Bennett is an Associate Professor in the University of Colorado School of Medicine and a practicing pediatric ICU physician and informaticist/data scientist with research concentrations in predictive analytics, electronic health record (EHR) data, and clinical decision support (CDS) tool implementation. He is the Informatics Director for the Colorado Clinical and Translational Sciences Institute (CCTSI) and Vice Chair of Clinical Informatics in the Department of Biomedical Informatics. His combined leadership roles have enabled him to build a rich mentoring environment for patient-oriented informatics research. This K24 application proposes to sustain and grow that mentorship program. He currently mentors clinician-scientists in a variety of clinical fields including intensive care, pharmacy, surgery, endocrinology, malignant hematology, and clinical psychology. The K24 Mentoring Plan aligns with Dr. Bennett’s mission to grow patient-oriented research using informatics and data science methods and tools. The mentoring plan leverages educational, career development, and research support programs available through the CCTSI and the new Department. The K24 Research Plan is to develop and implement machine learning and computational physiology models deployable as EHR-based CDS tools. Dr. Bennett currently leads and mentors projects developing CDS tools in both outpatient and inpatient care settings and in a variety of clinical domains include heart failure, traumatic brain injury, serious bacterial infection and sepsis, COVID- 19, thyroid cancer, and postpartum depression. In this K24, developing CDS tools to improve decision-making and outcomes in children with acute respiratory failure (ARF) is a natural next step in this work. ARF is a common, important, and NIH-relevant condition that causes significant pediatric morbidity and mortality. The aims of the project are to 1) develop and validate a dynamic machine learning-based real-time prediction model for intubation in children with ARF and 2) phenotype current lung injury state in mechanically ventilated children using computational physiology models. These models can be deployed as CDS tools and tested as interventions in future clinical trials to improve patient outcomes. The K24 Career Development Plan includes formal mentorship training and coursework in signal processing and dynamical systems models. This group of skills will make Dr. Bennett a more successful mentor.", "keywords": [ "Acceleration", "Acute respiratory failure", "Address", "Adult", "Ambulatory Care", "Bacteremia", "Bacterial Infections", "Biological Models", "Blood", "Breathing", "COVID-19", "Carbon Dioxide", "Caring", "Cause of Death", "Child", "Childhood", "Childhood Injury", "Clinical", "Clinical Data", "Clinical Informatics", "Clinical Psychology", "Clinical Sciences", "Clinical Trials", "Collaborations", "Colorado", "Critically ill children", "Data", "Data Science", "Data Scientist", "Decision Making", "Development", "Development Plans", "Education", "Electronic Health Record", "Endocrinology", "Environment", "Etiology", "Evaluation", "Excision", "Future", "Goals", "Grant", "Heart failure", "Hematology", "Individual", "Informatics", "Intensive Care", "Intervention", "Intubation", "Lead", "Leadership", "Link", "Machine Learning", "Malignant - descriptor", "Malignant neoplasm of thyroid", "Mechanical ventilation", "Medicine", "Mentors", "Mentorship", "Methods", "Mid-Career Clinical Scientist Award (K24)", "Midcareer Investigator Award in Patient-Oriented Research", "Mission", "Modeling", "Monitor", "Morbidity - disease rate", "National Heart Lung and Blood Institute", "Operative Surgical Procedures", "Outcome", "Patient-Focused Outcomes", "Patients", "Pharmacy facility", "Phenotype", "Physicians", "Physiology", "Postpartum Depression", "Predictive Analytics", "Procedures", "Prospective cohort study", "Registries", "Research", "Research Personnel", "Research Support", "Research Training", "Resources", "Respiratory System", "Risk", "Role", "Scientist", "Sedation procedure", "Sepsis", "Structure", "Testing", "Time", "Training", "Training Programs", "Translating", "Translational Research", "Translations", "Traumatic Brain Injury", "Tube", "United States National Institutes of Health", "Universities", "Ventilator", "Ventilator-induced lung injury", "Work", "biomedical informatics", "career", "career development", "clinical decision support", "design", "dynamic system", "experience", "implementation tool", "improved", "improved outcome", "inpatient service", "investigator training", "lung injury", "machine learning model", "mathematical model", "medical schools", "mid-career faculty", "mortality", "novel strategies", "patient oriented", "patient oriented research", "physiologic model", "predictive modeling", "programs", "prospective", "research and development", "resp" ], "approved": true } }, { "type": "Grant", "id": "15173", "attributes": { "award_id": "1K23HL171862-01A1", "title": "Myeloid-derived suppressor cells modulate disease severity in children with viral lower respiratory tract infections", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31460, "first_name": "BEENA G", "last_name": "Sood", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-01", "end_date": "2029-08-31", "award_amount": 180199, "principal_investigator": { "id": 31758, "first_name": "Katherine", "last_name": "Bline", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 879, "ror": "", "name": "RESEARCH INST NATIONWIDE CHILDREN'S HOSP", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "Severe lower respiratory tract infection (LRTI) due to viral pathogens remains one of the most common causes of death for young children worldwide. Current management of patients with viral-induced LRTI focuses on supportive care, but outcomes may be improved by augmenting the host immune response to fight the virus and regain immune homeostasis. A growing body of literature suggests that children with severe viral LRTI have an impaired adaptive immune response, specifically decreased T cell proliferation and cytokine production. Myeloid- derived suppressor cells (MDSC) are a heterogeneous cell population that expand during inflammatory conditions and potently inhibit T cell proliferation and function. MDSC have been extensively studied in adult oncologic populations where clinical trials show promising results of improved outcomes by inhibiting MDSC as part of chemotherapy and anti-tumor vaccine treatment regimens. Our group has identified significant increases in the frequency of MDSC populations in children with septic shock and COVID-19 and demonstrated associations between increased percentages of MDSC and worse clinical outcomes. However, it is unknown what role MDSC play in children with viral-induced severe LRTI. The overall goal of this proposal is to identify MDSC as contributors to the immune response in children with viral LRTI and identify mechanistic pathways as potential therapeutic targets for future investigations. Our central hypothesis is that increased frequency of MDSC will be associated with worse clinical outcomes and decreased numbers of CD4+ and CD8+ T cells in children with viral LRTI, and that pediatric MDSC-induced T cell suppression is reversible through inhibition of the PD-1 pathway. The proposed experiments will involve blood sampling of children with PCR-confirmed viral LRTI to characterize the dynamics of MDSC and lymphocyte populations during hospitalization. We will also use our in vitro model of MDSC induced from pediatric peripheral blood mononuclear cells and select patient samples to establish the PD-1 pathway as an important mechanism of MDSC-mediated inhibition of T cell proliferation and cytokine production in children. This career development award will generate the necessary data to inform the design of future studies of the pediatric immune response in severe lower respiratory tract infections and will equip me with the necessary tools to achieve independence as a patient- oriented clinician-scientist.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14789", "attributes": { "award_id": "1F31CA281335-01", "title": "Examining Early Life Risk Factors and Patterns of Screening for Early-Onset Colorectal Cancer", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31478, "first_name": "SANGEETA AHUJA", "last_name": "Ghosh", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-18", "end_date": "2025-08-17", "award_amount": 47694, "principal_investigator": { "id": 31479, "first_name": "Arfan", "last_name": "Siddique", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "In the United States (US), the incidence of early-onset colorectal cancer (EOCRC), defined as colorectal cancer (CRC) diagnosed among individuals <50 years of age, has been increasing rapidly. Compared to late- onset CRC (i.e., CRC diagnosed among individuals ≥50 years of age), EOCRC is characterized by more aggressive pathology and distinct genetic profiles, indicating that the etiology of EOCRC may be distinct. There have been a limited number of studies examining the risk factors of EOCRC, and none have focused on early life risk factors, which could be particularly relevant to early-onset diseases. Over the past few years, the American Cancer Society and the US Preventative Services Task Force reduced the recommended age of CRC screening from 50 years to 45 years, and the COVID-19 pandemic influenced the provision of preventative services across the country. These events could impact the temporal and geographic patterns of screening for EOCRC, but no study has systematically assessed such impacts in a large sample of the US population. The proposed study aims to 1) identify early-life risk factors of EOCRC and 2) evaluate spatiotemporal patterns of EOCRC screening in the US. For the first aim, we will conduct a nested case-control study within the California birth cohort and compare the birth characteristics between 1200 EOCRC cases and 60,000 control subjects matched on year of birth. In addition, we will obtain birth address matched social, behavioral, lifestyle, and environmental factors from the Centers for Disease Control and Prevention and the Environmental Protection Agency and compare these neighborhood-level factors between the 1,200 cases and 60,000 controls. Two key methodological challenges will be addressed: a) spatial autocorrelation, the tendency of adjacent geographic units to share similar attributes; b) the modifiable areal unit problem, a biasing effect that occurs when observed associations between exposures and outcomes vary based on the scale of the chosen geographic unit. For the second aim, we will assess temporal patterns in EOCRC screening and identify factors associated with potential regional variation in screening by leveraging unique claims data from Blue Cross Blue Shield (BCBS), the largest insurance provider in the US that covers one-third of all Americans. Approximately 4 million beneficiaries aged 45-49 years are enrolled in BCBS each year, allowing us a great opportunity to assess both stool-based and structural CRC screening tests. With a rigorous design and unparalleled sample sizes, the proposed study addresses research questions with clear public health significance, is very innovative, and will probably yield a high impact on our knowledge about the etiology and screening of EOCRC – a critically understudied field according to the National Cancer Institute. In addition, by bringing together a multidisciplinary team of experts in cancer epidemiology, health services research, spatial statistics, gastrointestinal oncology, and geographic information systems science, this study will contribute to the training of a promising minority predoctoral fellow with aspirations to pursue a career in cancer epidemiology research and improve the health status for all.", "keywords": [ "Address", "Adoption", "Age", "Age Years", "Air", "American", "American Cancer Society", "Atlases", "Behavioral", "Birth", "Birth Records", "Birth Weight", "Blue Cross", "Blue Shield", "COVID-19 pandemic", "California", "Caring", "Censuses", "Centers for Disease Control and Prevention (U.S.)", "Characteristics", "Chronic Disease", "Classification", "Colorectal Cancer", "Country", "Data", "Databases", "Disparity", "Early identification", "Encapsulated", "Enrollment", "Environmental Risk Factor", "Etiology", "Event", "Excision", "Feces", "Gastroenterologist", "Genetic", "Geographic Information Systems", "Geographic Locations", "Geography", "Guidelines", "Health", "Health Services Research", "Health Status", "Healthcare", "Hospital Referrals", "Incidence", "Individual", "Insurance", "Interruption", "Intervention", "Knowledge", "Life", "Life Style", "Light", "Link", "Malignant Neoplasms", "Maternal Age", "Menstruation", "Methodology", "Minority", "Modeling", "National Cancer Institute", "Neighborhoods", "Nested Case-Control Study", "Oncology", "Onset of illness", "Outcome", "Pathology", "Patients", "Pattern", "Persons", "Physical environment", "Population", "Predisposition", "Prevalence", "Prevention strategy", "Preventive service", "Primary Prevention", "Probability", "Provider", "Public Health", "Recommendation", "Research", "Resources", "Risk", "Risk Assessment", "Risk Factors", "Sample Size", "Sampling", "Science", "Secondary Prevention", "Social Environment", "Socioeconomic Status", "Symptoms", "Testing", "Time", "Time Series Analysis", "Time trend", "Training", "United States", "United States Environmental Protection Agency", "United States Preventative Services Task Force", "Update", "Variant", "age group", "aged", "aspirate", "beneficiary", "cancer diagnosis", "cancer epidemiology", "career", "cohort", "colorectal cancer prevention", "colorectal cancer risk", "colorectal cancer screening", "contextual factors", "data registry", "design", "disorder risk", "early onset", "early onset colorectal cancer", "early screening", "epidemiology study", "gastrointestinal", "high risk", "high risk population", "improved", "innovation", "lifestyle factors", "multidisciplinary", "neoplasm registry", "population based", "pre-doctoral", "response", "screening", "screening guidelines", "social", "sociodemographics", "spatiotemporal", "statistics", "therapy design", "uptake" ], "approved": true } }, { "type": "Grant", "id": "14801", "attributes": { "award_id": "5R01MD017870-02", "title": "Implementing Scalable, PAtient-centered Team-based Care for Adults with Type 2 Diabetes and Health Disparities (iPATH)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 31480, "first_name": "Lynne Slaughter", "last_name": "Padgett", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-21", "end_date": "2028-01-31", "award_amount": 656909, "principal_investigator": { "id": 27899, "first_name": "Sara Jean", "last_name": "Singer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT A collaborative network of research teams from Stanford, Harvard, The Ohio State University, and Impactivo, LLC propose practice-relevant research focused on diabetes care in federally qualified health centers (FQHCs). Some 37.3 million Americans have type 2 diabetes and significant racial and socioeconomic disparities persist in care quality and patient safety. FQHCs serve 1 in 7 U.S. racial/ethnic minorities and shoulder a higher prevalence of diabetes (21% FQHC, 11% U.S.), offering a promising venue for innovating in equity-focused diabetes care. The iPATH project will refine and implement an approach to practice transformation originally conceived to support FQHCs’ pursuit of National Committee for Quality Assurance recognition as patient-centered medical homes. A pilot demonstrated significant decreases (average 31% reduction) in poorly controlled diabetes (A1c>9%) among patients at 7 clinics affiliated with an FQHC in Puerto Rico in 2017-20. Improvements in patients’ diabetes control were sustained pre- to post- Covid-19 pandemic. Aim 1. Refine the iPATH implementation approach by identifying organizational conditions and processes at FQHCs that promoted or impeded the effectiveness of type 2 diabetes care for NIH- designated U.S. health disparity populations pre- and post-pandemic. Research teams will simultaneously conduct 12 in-depth regional case studies, enabling contrast between FQHCs considered high- performing and low-performing for diabetes control. Teams will identify actionable, how-to implementation factors for ensuring chronic, preventive, and acute care for patients with diabetes. Employing an innovative Rapid Data Collection and Reporting methodology, teams will rapidly collect, analyze, and share data to accelerate dissemination of customized feedback to FQHC leaders and to inform adaptation and implementation of the iPATH practice transformation. Aim 2. Implement a multi-level, multi-component, technology-enabled practice transformation strategy to improve type 2 diabetes for patients at 8 multi-clinic FQHCs. Teams will adapt, tailor, implement, test, and spread an equity-focused practice transformation strategy across FQHCs located in California, Massachusetts, Ohio, and Puerto Rico. The iPATH implementation approach will be modularized and customizable to accommodate organizational readiness, patient needs, and social contexts, tailoring practice transformation efforts to each unique FQHC. Aim 3. Comprehensively evaluate the iPATH implementation approach with a hybrid type 2 study, including a stepped wedge cluster randomized trial. Including formative, process, and summative evaluation elements guided by the Exploration-Preparation-Implementation-Sustainment model, the study will evaluate impact of practice transformation and identify process elements affecting implementation effectiveness. Analyses will leverage FQHC data by race and ethnicity to examine health disparities.", "keywords": [ "Acceleration", "Address", "Adopted", "Adult", "Affect", "American", "COVID-19 pandemic", "California", "Caring", "Case Study", "Chronic Care", "Clinic", "Clinical Data", "Cluster randomized trial", "Data", "Data Analyses", "Data Collection", "Data Reporting", "Diabetes Mellitus", "Effectiveness", "Elements", "Ensure", "Environment", "Equity", "Ethnic Origin", "Evaluation", "Exploration Preparation Implementation and Sustainment", "Federally Qualified Health Center", "Feedback", "Geographic Locations", "Glycosylated hemoglobin A", "Goals", "Guidelines", "High Prevalence", "Hybrids", "Inequity", "Interview", "Investments", "Massachusetts", "Medical Economics", "Methodology", "Methods", "Modeling", "National Committee for Quality Assurance", "Non-Insulin-Dependent Diabetes Mellitus", "Not Hispanic or Latino", "Ohio", "Outcome", "Patient Care", "Patients", "Pilot Projects", "Population", "Prevalence", "Preventive care", "Privatization", "Process", "Puerto Rico", "Quality of Care", "Race", "Recommendation", "Research", "SARS-CoV-2 infection", "Science", "Shoulder", "Social Environment", "Source", "Standardization", "Symptoms", "Technology", "Testing", "United States Agency for Healthcare Research and Quality", "United States National Institutes of Health", "Universities", "Variant", "acute care", "behavioral economics", "care delivery", "data sharing", "diabetes control", "ethnic minority", "experience", "flexibility", "health care quality", "health disparity", "health disparity populations", "health equity", "high risk", "implementation determinants", "implementation/effectiveness", "improved", "innovation", "minority patient", "novel", "novel strategies", "organizational readiness", "pandemic disease", "pandemic disruption", "patient centered medical home", "patient oriented", "patient safety", "poor health outcome", "post-COVID-19", "post-pandemic", "pre-pandemic", "racial disparity", "racial minority", "remote health care", "socioeconomic disparity", "socioeconomics", "team-based care", "tool" ], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1424, "count": 14236 } } }